NASHUA, N.H., Nov. 10, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first step in the development of a new strategic multi-year commercial agreement and an initial order with Radiology Partners, the largest radiology practice in the U.S. This planned collaboration will solidify iCAD’s position as Radiology Partners’ provider of breast AI solutions and will leverage Radiology Partners’ clinical expertise, scale and leadership position to expand access to iCAD’s Breast AI Suite to thousands of physicians and millions of patients.

“As we continue to deliver on our mission to elevate the quality of breast cancer screening, the expected execution of a collaboration agreement will mark a key step forward in our ability to provide access to our unparalleled portfolio to significantly more radiologists, practices and patients nationwide,” said Stacey Stevens, President and CEO of iCAD, Inc. “Nationally recognized for their clinical leadership in mammography screening, Radiology Partners provides mammography services to millions of women per year across more than 3,000 facilities, including the top ten largest health systems in the country, making them an exceptional partner. This partnership will mark a tremendous milestone achievement for iCAD and will represent an exciting opportunity to aggressively expand access to our technology to more women.”

The company has already received its first order from Radiology Partners, allowing hundreds of thousands of women to be screened at Radiology Partners’ owned outpatient imaging center sites with iCAD’s Breast AI Suite. iCAD’s technology can be deployed to the Radiology Partners network via the Radiology Partners Cloud, significantly increasing the potential for adoption across their network of facilities and unleashing the ability to improve mammography screening for millions of women across the country.
iCAD’s Breast AI Suite is the only complete portfolio of first-in-kind, clinically proven technologies for the detection of breast cancer, automated breast density assessment and short-term personal risk evaluation. The portfolio includes: ProFound AI®, the first AI cancer detection software for 3D mammography to be cleared by the FDA; PowerLook® Breast Density Assessment, which aids in accurate and consistent density-based stratification and reporting; and ProFound AI® Risk, the world's first and only clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman based on age, breast density and mammographic features.

Women's Health Homepage